These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17146377)

  • 21. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
    Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
    Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
    Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
    Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial.
    Hadjadj S; Gourdy P; Zaoui P; Guerci B; Roudaut N; Gautier JF; Chabin M; Mauco G; Ragot S;
    Diabet Med; 2007 Aug; 24(8):906-10. PubMed ID: 17451421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive function in postmenopausal women treated with raloxifene.
    Yaffe K; Krueger K; Sarkar S; Grady D; Barrett-Connor E; Cox DA; Nickelsen T;
    N Engl J Med; 2001 Apr; 344(16):1207-13. PubMed ID: 11309635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
    Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats.
    Ammann P; Bourrin S; Brunner F; Meyer JM; Clément-Lacroix P; Baron R; Gaillard M; Rizzoli R
    Bone; 2004 Jul; 35(1):153-61. PubMed ID: 15207751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
    Engin-Ustün Y; Ustün Y; Meydanli MM; Kafkasli A
    Gynecol Endocrinol; 2006 Dec; 22(12):676-9. PubMed ID: 17162709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
    Johansson H; Bonanni B; Mariette F; Cazzaniga M; Baglietto L; Guerrieri-Gonzaga A; Sandri MT; Luini A; Pelosi G; Decensi A
    Breast Cancer Res Treat; 2006 Jul; 98(2):167-72. PubMed ID: 16538534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.
    Neven P; Quail D; Marin F; Creatsas G; Depypere H; Rechberger T; Liu-Léage S; Pavo I; Schmitt H; Nickelsen T
    Maturitas; 2005 Oct; 52(2):87-101. PubMed ID: 15967604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.